The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain - PubMed
2 hours ago
- #PET Tracer
- #Alpha-synuclein
- #Neurodegenerative Diseases
- The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain for potential use in synucleinopathies like multiple system atrophy (MSA) and Parkinson's disease.
- In vitro and preclinical studies show [11C]MODAG-005 has subnanomolar binding affinity to alpha-synuclein fibrils and inclusions, good brain penetration, rapid clearance, and low metabolite formation.
- In vivo validation in rodent and nonhuman primate models, including alpha-synuclein fibril-injected rats and transgenic mice, demonstrates pronounced binding and a good signal-to-noise ratio correlating with pathological load.
- First-in-human imaging in patients with MSA cerebellar type, MSA cerebellar and parkinsonian type, and Parkinson's disease shows [11C]MODAG-005 binding in brain regions affected by alpha-synuclein pathology.
- The tracer also supports therapeutic development by showing target engagement of the drug candidate anle138b in brain tissues from models and patients, highlighting its potential for diagnosis and treatment monitoring.